News summary

Rivus to show animal data on muscle-sparing GLP-1

Source: Longevity Technology • Published: 30 Oct 2026, 17:57

Summarized by Masters of Longevity from Longevity Technology.

Preclinical NHP and mouse data show RV‑8451 may spare muscle while reducing fat.

Rivus to show animal data on muscle-sparing GLP-1
Key Takeaways
  • Results are from non‑human primates and mouse models.
  • Findings were reported preclinically and were not tested in humans.
  • Poster abstracts have not established effect sizes or reproducibility.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.